117. Syringomyelia Clinical trials / Disease details
Clinical trials : 3 / Drugs : 5 - (DrugBank : 1) / Drug target gene : 0 - Drug target pathway : 0
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2000039678 | 2021-02-01 | 2020-11-05 | Evaluation of Posterior Fossa Decompression (PFD) without or with Cerebellar Tonsil Thermocoagulation (PFDCT) for Arnold-Chiari Malformation Type I with Syringomyelia: a ramdomised controlled trial | Evaluation of Posterior Fossa Decompression (PFD) without or with Cerebellar Tonsil Thermocoagulation (PFDCT) for Arnold-Chiari Malformation Type I with Syringomyelia: a ramdomised controlled trial | Arnold-Chiari Malformation Type I with Syringomyelia | A Group:Posterior Fossa Decompression;B Group:Posterior Fossa Decompression (PFD) with Cerebellar tonsil Thermocoagulation (PFDCT); | Fujian Medical University Union Hospital | NULL | Recruiting | 18 | 65 | Both | A Group:70;B Group:70; | China | |
| 2 | NCT02807142 (ClinicalTrials.gov) | March 2016 | 3/6/2016 | Efficacy Assessment of the Cell Therapy Medicine NC1 in Patients With Post-traumatic Syringomyelia | Efficacy Assessment of the Cell Therapy Medicine NC1 in Patients With Post-traumatic Syringomyelia | Post-Traumatic Syringomyelia | Biological: NC 1 cell therapy | Puerta de Hierro University Hospital | NULL | Completed | 18 Years | 70 Years | All | 6 | Phase 2 | NULL |
| 3 | EUCTR2015-002383-16-ES (EUCTR) | 19/01/2016 | 15/10/2015 | Evaluate the efficacy of the cell therapy with NC1 medication in patients with post-traumatic syringomyelia | Evaluate the efficacy of the cell therapy with NC1 medication in patients with post-traumatic syringomyelia | Traumatic spinal cord injury, chronically established, associated with syringomyelia and neurological deficit considered irreversible.;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Células mesenquimales troncales adultas autólogas de medula ósea expandidas Product Code: CME-LEM4 INN or Proposed INN: células mesenquimales troncales adultas autólogas de médula ósea expandidas | Fundación Investigación Biomédica Hospital Universitario Puerta de Hierro | NULL | Not Recruiting | Female: yes Male: yes | 6 | Phase 2 | Spain |